Britt A. Sterken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Britt A. Sterken has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Cornelis F. Calkhoven
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG) University of Groningen Groningen the Netherlands
2 shared publications Gertrud Kortman
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications- Alain de Bruin
Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands
1 shared publication Alejandra Hernandez-Segura
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publicationChristine Müller
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication- Christine Müller
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG) University of Groningen Groningen the Netherlands
1 shared publication
Latest Publications
- Open Access
- 18 January 2022
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-13
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells
The transcription factor C/EBPβ is a master regulator of mammary gland development and tissue remodelling during lactation. TheCEBPB-mRNA is translated into three distinct protein isoforms named C/EBPβ-LAP1, -LAP2 and -LIP that are functionally different. The smaller isoform LIP lacks the N-terminal transactivation domains and is considered to act as an inhibitor of the transactivating LAP1/2 isoforms by competitive binding for the same DNA recognition sequences. Aberrantly high expression of LIP is associated with mammary epithelial proliferation and is found in grade III, estrogen receptor (ER) and progesterone (PR) receptor-negative human breast cancer. Here, we show that reverting the high LIP/LAP ratios in triple-negative breast cancer (TNBC) cell lines into low LIP/LAP ratios by overexpression of LAP reduces migration and matrix invasion of these TNBC cells. In addition, in untransformed MCF10A human mammary epithelial cells overexpression of LIP stimulates migration. Knockout ofCEBPBin TNBC cells where LIP expression prevails, resulted in strongly reduced migration that was accompanied by a downregulation of genes involved in cell migration, extracellular matrix production and cytoskeletal remodelling, many of which are epithelial to mesenchymal transition (EMT) marker genes. Together, this study suggests that the LIP/LAP ratio is involved in regulating breast cancer cell migration and invasion. This study together with studies from others shows that understanding the functions the C/EBPβ-isoforms in breast cancer development may reveal new avenues of treatment.
- 18 January 2022
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-13
Open AccessC/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells
The transcription factor C/EBPβ is a master regulator of mammary gland development and tissue remodelling during lactation. TheCEBPB-mRNA is translated into three distinct protein isoforms named C/EBPβ-LAP1, -LAP2 and -LIP that are functionally different. The smaller isoform LIP lacks the N-terminal transactivation domains and is considered to act as an inhibitor of the transactivating LAP1/2 isoforms by competitive binding for the same DNA recognition sequences. Aberrantly high expression of LIP is associated with mammary epithelial proliferation and is found in grade III, estrogen receptor (ER) and progesterone (PR) receptor-negative human breast cancer. Here, we show that reverting the high LIP/LAP ratios in triple-negative breast cancer (TNBC) cell lines into low LIP/LAP ratios by overexpression of LAP reduces migration and matrix invasion of these TNBC cells. In addition, in untransformed MCF10A human mammary epithelial cells overexpression of LIP stimulates migration. Knockout ofCEBPBin TNBC cells where LIP expression prevails, resulted in strongly reduced migration that was accompanied by a downregulation of genes involved in cell migration, extracellular matrix production and cytoskeletal remodelling, many of which are epithelial to mesenchymal transition (EMT) marker genes. Together, this study suggests that the LIP/LAP ratio is involved in regulating breast cancer cell migration and invasion. This study together with studies from others shows that understanding the functions the C/EBPβ-isoforms in breast cancer development may reveal new avenues of treatment.
- 18 June 2021
- Published by University of Groningen Press
Functions of the C/EBPβ isoforms in breast cancer
- 18 June 2021
- Published by University of Groningen Press
Functions of the C/EBPβ isoforms in breast cancer
- Open Access
- 14 June 2019
- Published by Springer Nature in Communications Biology
- Vol. 2 (1) , 208
C/EBPβ-LIP induces cancer-type metabolic reprogramming by regulating the let-7/LIN28B circuit in mice
The transcription factors LAP1, LAP2 and LIP are derived from theCebpb-mRNA through the use of alternative start codons. High LIP expression has been associated with human cancer and increased cancer incidence in mice. However, how LIP contributes to cellular transformation is poorly understood. Here we present that LIP induces aerobic glycolysis and mitochondrial respiration reminiscent of cancer metabolism. We show that LIP-induced metabolic programming is dependent on the RNA-binding protein LIN28B, a translational regulator of glycolytic and mitochondrial enzymes with known oncogenic function. LIP activates LIN28B through repression of thelet-7microRNA family that targets theLin28b-mRNA. Transgenic mice overexpressing LIP have reduced levels oflet-7and increased LIN28B expression, which is associated with metabolic reprogramming as shown in primary bone marrow cells, and with hyperplasia in the skin. This study establishes LIP as an inducer of cancer-type metabolic reprogramming and as a regulator of thelet-7/LIN28B regulatory circuit.
- 14 June 2019
- Published by Springer Nature in Communications Biology
- Vol. 2 (1) , 208
Open AccessC/EBPβ-LIP induces cancer-type metabolic reprogramming by regulating the let-7/LIN28B circuit in mice
The transcription factors LAP1, LAP2 and LIP are derived from theCebpb-mRNA through the use of alternative start codons. High LIP expression has been associated with human cancer and increased cancer incidence in mice. However, how LIP contributes to cellular transformation is poorly understood. Here we present that LIP induces aerobic glycolysis and mitochondrial respiration reminiscent of cancer metabolism. We show that LIP-induced metabolic programming is dependent on the RNA-binding protein LIN28B, a translational regulator of glycolytic and mitochondrial enzymes with known oncogenic function. LIP activates LIN28B through repression of thelet-7microRNA family that targets theLin28b-mRNA. Transgenic mice overexpressing LIP have reduced levels oflet-7and increased LIN28B expression, which is associated with metabolic reprogramming as shown in primary bone marrow cells, and with hyperplasia in the skin. This study establishes LIP as an inducer of cancer-type metabolic reprogramming and as a regulator of thelet-7/LIN28B regulatory circuit.